SALBUMOL (salbutamol), beta-2 agonist – labour inhibitor

Insufficient clinical benefit to justify its reimbursement in the short-term treatment of uncomplicated preterm labour and in emergency use in specific obstetric scenarios due to potentially severe maternal adverse cardiopulmonary effects

• SALBUMOL has MA for the short-term treatment of uncomplicated premature labour and for emergency use in specific obstetric scenarios.

• Betamimetic tocolytics are not recommended due to the existence of potentially severe maternal adverse cardiopulmonary effects.

• SALBUMOL no longer has a role in the therapeutic strategy